Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China

This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of v...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human vaccines & immunotherapeutics 2021-09, Vol.17 (9), p.2863-2867
Hauptverfasser: Wang, Guangfei, Zhu, Lin, Zhu, Yiqing, Ye, Qiaofeng, Yu, Xin, Fu, Meng, Lu, Jinmiao, Li, Xiaoxia, Huang, Yidie, Zhang, Junqi, Lan, Jianger, Li, Ziwei, Zhai, Xiaowen, Xu, Hong, Li, Zhiping
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2867
container_issue 9
container_start_page 2863
container_title Human vaccines & immunotherapeutics
container_volume 17
creator Wang, Guangfei
Zhu, Lin
Zhu, Yiqing
Ye, Qiaofeng
Yu, Xin
Fu, Meng
Lu, Jinmiao
Li, Xiaoxia
Huang, Yidie
Zhang, Junqi
Lan, Jianger
Li, Ziwei
Zhai, Xiaowen
Xu, Hong
Li, Zhiping
description This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of vaccination was monitored by clinical pharmacists, and the occurrence, types, severity of adverse reactions were recorded in detail. Through the investigation and analysis on the safety of COVID-19 vaccination of the 2305 people, the important role and value of clinical pharmacists in the vaccination process was elaborated. Common adverse reactions included local pain, dizziness and fatigue, with the incidence rates of 2.09%, 0.67% and 0.49%, respectively. Others such as headache, nausea, skin itching, cough, palpitation, dry mouth, hand anesthesia, local induration, muscle soreness, local rash, and chill had incidence rates of less than 0.30%. Three cases of serious adverse events that occurred in this vaccination returned to normal after treatment, with no subsequent discomfort. Clinical pharmacists played an important role in the safety monitoring of COVID-19 vaccination. The safety of the inactivated COVID-19 vaccine is good. Most of the common adverse reactions were mild and tolerable, with generally low incidence. The work of clinical pharmacists is important and can be expanded in the future to ensure the safety of vaccination and to provide better health care service.
doi_str_mv 10.1080/21645515.2021.1913964
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_21645515_2021_1913964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_76c4bd82362d49f1b7881436fe12f78b</doaj_id><sourcerecordid>2518226960</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-de93b45f171d3f097f6e6b51e8914cefe33be843535f8c9edc56a5ee46ec2b5b3</originalsourceid><addsrcrecordid>eNp9kUuP0zAURiMEYkbD_ASQl2xScv2Ks0GgDo9KI82Ch5BYWI5z3XqUxMVOi_LvcWmnYjZ4Y-v63O_aOkXxEqoFVKp6Q0FyIUAsaEVhAQ2wRvInxeWhXgrBfzw9n0FcFNcp3Vd51RXlUj4vLhhTSnKAy-LnF-NwmknaxT3OpJ2J7f3orenJdmPiYKxPUyJhJMu776ubEhqyN9b60Uw-F10MAzEk-XHdI7E4ThiJz_AmEy-KZ870Ca9P-1Xx7eOHr8vP5e3dp9Xy_W1pBeNT2WHDWi4c1NAxVzW1kyhbAaga4BYdMtai4kww4ZRtsLNCGoHIJVraipZdFatjbhfMvd5GP5g462C8_lsIca1NnLztUdfS8rZTlEna8cZBWysFnEmHQF2tDllvj1nbXTvkUflH0fSPQh_fjH6j12GvFVOgKOSA16eAGH7tME168Mli35sRwy5pKjJGZSOrjIojamNIKaI7j4FKHzzrB8_64FmfPOe-V_--8dz1YDUD746AH13IDn-H2Hd6MnMfootmzE41-_-MPz5mt3A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2518226960</pqid></control><display><type>article</type><title>Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China</title><source>MEDLINE</source><source>PubMed (Medline)</source><source>Alma/SFX Local Collection</source><creator>Wang, Guangfei ; Zhu, Lin ; Zhu, Yiqing ; Ye, Qiaofeng ; Yu, Xin ; Fu, Meng ; Lu, Jinmiao ; Li, Xiaoxia ; Huang, Yidie ; Zhang, Junqi ; Lan, Jianger ; Li, Ziwei ; Zhai, Xiaowen ; Xu, Hong ; Li, Zhiping</creator><creatorcontrib>Wang, Guangfei ; Zhu, Lin ; Zhu, Yiqing ; Ye, Qiaofeng ; Yu, Xin ; Fu, Meng ; Lu, Jinmiao ; Li, Xiaoxia ; Huang, Yidie ; Zhang, Junqi ; Lan, Jianger ; Li, Ziwei ; Zhai, Xiaowen ; Xu, Hong ; Li, Zhiping</creatorcontrib><description>This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of vaccination was monitored by clinical pharmacists, and the occurrence, types, severity of adverse reactions were recorded in detail. Through the investigation and analysis on the safety of COVID-19 vaccination of the 2305 people, the important role and value of clinical pharmacists in the vaccination process was elaborated. Common adverse reactions included local pain, dizziness and fatigue, with the incidence rates of 2.09%, 0.67% and 0.49%, respectively. Others such as headache, nausea, skin itching, cough, palpitation, dry mouth, hand anesthesia, local induration, muscle soreness, local rash, and chill had incidence rates of less than 0.30%. Three cases of serious adverse events that occurred in this vaccination returned to normal after treatment, with no subsequent discomfort. Clinical pharmacists played an important role in the safety monitoring of COVID-19 vaccination. The safety of the inactivated COVID-19 vaccine is good. Most of the common adverse reactions were mild and tolerable, with generally low incidence. The work of clinical pharmacists is important and can be expanded in the future to ensure the safety of vaccination and to provide better health care service.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2021.1913964</identifier><identifier>PMID: 33886411</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Child ; China - epidemiology ; clinical pharmacists ; COVID-19 ; COVID-19 Vaccines ; Humans ; Pharmacists ; Research Paper ; safety ; SARS-CoV-2 ; Vaccination ; vaccine</subject><ispartof>Human vaccines &amp; immunotherapeutics, 2021-09, Vol.17 (9), p.2863-2867</ispartof><rights>2021 Taylor &amp; Francis Group, LLC 2021</rights><rights>2021 Taylor &amp; Francis Group, LLC 2021 Taylor &amp; Francis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-de93b45f171d3f097f6e6b51e8914cefe33be843535f8c9edc56a5ee46ec2b5b3</citedby><cites>FETCH-LOGICAL-c534t-de93b45f171d3f097f6e6b51e8914cefe33be843535f8c9edc56a5ee46ec2b5b3</cites><orcidid>0000-0001-6194-023X ; 0000-0001-5132-9197 ; 0000-0001-5310-5306</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381821/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381821/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33886411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Guangfei</creatorcontrib><creatorcontrib>Zhu, Lin</creatorcontrib><creatorcontrib>Zhu, Yiqing</creatorcontrib><creatorcontrib>Ye, Qiaofeng</creatorcontrib><creatorcontrib>Yu, Xin</creatorcontrib><creatorcontrib>Fu, Meng</creatorcontrib><creatorcontrib>Lu, Jinmiao</creatorcontrib><creatorcontrib>Li, Xiaoxia</creatorcontrib><creatorcontrib>Huang, Yidie</creatorcontrib><creatorcontrib>Zhang, Junqi</creatorcontrib><creatorcontrib>Lan, Jianger</creatorcontrib><creatorcontrib>Li, Ziwei</creatorcontrib><creatorcontrib>Zhai, Xiaowen</creatorcontrib><creatorcontrib>Xu, Hong</creatorcontrib><creatorcontrib>Li, Zhiping</creatorcontrib><title>Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China</title><title>Human vaccines &amp; immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of vaccination was monitored by clinical pharmacists, and the occurrence, types, severity of adverse reactions were recorded in detail. Through the investigation and analysis on the safety of COVID-19 vaccination of the 2305 people, the important role and value of clinical pharmacists in the vaccination process was elaborated. Common adverse reactions included local pain, dizziness and fatigue, with the incidence rates of 2.09%, 0.67% and 0.49%, respectively. Others such as headache, nausea, skin itching, cough, palpitation, dry mouth, hand anesthesia, local induration, muscle soreness, local rash, and chill had incidence rates of less than 0.30%. Three cases of serious adverse events that occurred in this vaccination returned to normal after treatment, with no subsequent discomfort. Clinical pharmacists played an important role in the safety monitoring of COVID-19 vaccination. The safety of the inactivated COVID-19 vaccine is good. Most of the common adverse reactions were mild and tolerable, with generally low incidence. The work of clinical pharmacists is important and can be expanded in the future to ensure the safety of vaccination and to provide better health care service.</description><subject>Child</subject><subject>China - epidemiology</subject><subject>clinical pharmacists</subject><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>Pharmacists</subject><subject>Research Paper</subject><subject>safety</subject><subject>SARS-CoV-2</subject><subject>Vaccination</subject><subject>vaccine</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kUuP0zAURiMEYkbD_ASQl2xScv2Ks0GgDo9KI82Ch5BYWI5z3XqUxMVOi_LvcWmnYjZ4Y-v63O_aOkXxEqoFVKp6Q0FyIUAsaEVhAQ2wRvInxeWhXgrBfzw9n0FcFNcp3Vd51RXlUj4vLhhTSnKAy-LnF-NwmknaxT3OpJ2J7f3orenJdmPiYKxPUyJhJMu776ubEhqyN9b60Uw-F10MAzEk-XHdI7E4ThiJz_AmEy-KZ870Ca9P-1Xx7eOHr8vP5e3dp9Xy_W1pBeNT2WHDWi4c1NAxVzW1kyhbAaga4BYdMtai4kww4ZRtsLNCGoHIJVraipZdFatjbhfMvd5GP5g462C8_lsIca1NnLztUdfS8rZTlEna8cZBWysFnEmHQF2tDllvj1nbXTvkUflH0fSPQh_fjH6j12GvFVOgKOSA16eAGH7tME168Mli35sRwy5pKjJGZSOrjIojamNIKaI7j4FKHzzrB8_64FmfPOe-V_--8dz1YDUD746AH13IDn-H2Hd6MnMfootmzE41-_-MPz5mt3A</recordid><startdate>20210902</startdate><enddate>20210902</enddate><creator>Wang, Guangfei</creator><creator>Zhu, Lin</creator><creator>Zhu, Yiqing</creator><creator>Ye, Qiaofeng</creator><creator>Yu, Xin</creator><creator>Fu, Meng</creator><creator>Lu, Jinmiao</creator><creator>Li, Xiaoxia</creator><creator>Huang, Yidie</creator><creator>Zhang, Junqi</creator><creator>Lan, Jianger</creator><creator>Li, Ziwei</creator><creator>Zhai, Xiaowen</creator><creator>Xu, Hong</creator><creator>Li, Zhiping</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6194-023X</orcidid><orcidid>https://orcid.org/0000-0001-5132-9197</orcidid><orcidid>https://orcid.org/0000-0001-5310-5306</orcidid></search><sort><creationdate>20210902</creationdate><title>Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China</title><author>Wang, Guangfei ; Zhu, Lin ; Zhu, Yiqing ; Ye, Qiaofeng ; Yu, Xin ; Fu, Meng ; Lu, Jinmiao ; Li, Xiaoxia ; Huang, Yidie ; Zhang, Junqi ; Lan, Jianger ; Li, Ziwei ; Zhai, Xiaowen ; Xu, Hong ; Li, Zhiping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-de93b45f171d3f097f6e6b51e8914cefe33be843535f8c9edc56a5ee46ec2b5b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Child</topic><topic>China - epidemiology</topic><topic>clinical pharmacists</topic><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>Pharmacists</topic><topic>Research Paper</topic><topic>safety</topic><topic>SARS-CoV-2</topic><topic>Vaccination</topic><topic>vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Guangfei</creatorcontrib><creatorcontrib>Zhu, Lin</creatorcontrib><creatorcontrib>Zhu, Yiqing</creatorcontrib><creatorcontrib>Ye, Qiaofeng</creatorcontrib><creatorcontrib>Yu, Xin</creatorcontrib><creatorcontrib>Fu, Meng</creatorcontrib><creatorcontrib>Lu, Jinmiao</creatorcontrib><creatorcontrib>Li, Xiaoxia</creatorcontrib><creatorcontrib>Huang, Yidie</creatorcontrib><creatorcontrib>Zhang, Junqi</creatorcontrib><creatorcontrib>Lan, Jianger</creatorcontrib><creatorcontrib>Li, Ziwei</creatorcontrib><creatorcontrib>Zhai, Xiaowen</creatorcontrib><creatorcontrib>Xu, Hong</creatorcontrib><creatorcontrib>Li, Zhiping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines &amp; immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Guangfei</au><au>Zhu, Lin</au><au>Zhu, Yiqing</au><au>Ye, Qiaofeng</au><au>Yu, Xin</au><au>Fu, Meng</au><au>Lu, Jinmiao</au><au>Li, Xiaoxia</au><au>Huang, Yidie</au><au>Zhang, Junqi</au><au>Lan, Jianger</au><au>Li, Ziwei</au><au>Zhai, Xiaowen</au><au>Xu, Hong</au><au>Li, Zhiping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China</atitle><jtitle>Human vaccines &amp; immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2021-09-02</date><risdate>2021</risdate><volume>17</volume><issue>9</issue><spage>2863</spage><epage>2867</epage><pages>2863-2867</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of vaccination was monitored by clinical pharmacists, and the occurrence, types, severity of adverse reactions were recorded in detail. Through the investigation and analysis on the safety of COVID-19 vaccination of the 2305 people, the important role and value of clinical pharmacists in the vaccination process was elaborated. Common adverse reactions included local pain, dizziness and fatigue, with the incidence rates of 2.09%, 0.67% and 0.49%, respectively. Others such as headache, nausea, skin itching, cough, palpitation, dry mouth, hand anesthesia, local induration, muscle soreness, local rash, and chill had incidence rates of less than 0.30%. Three cases of serious adverse events that occurred in this vaccination returned to normal after treatment, with no subsequent discomfort. Clinical pharmacists played an important role in the safety monitoring of COVID-19 vaccination. The safety of the inactivated COVID-19 vaccine is good. Most of the common adverse reactions were mild and tolerable, with generally low incidence. The work of clinical pharmacists is important and can be expanded in the future to ensure the safety of vaccination and to provide better health care service.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>33886411</pmid><doi>10.1080/21645515.2021.1913964</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-6194-023X</orcidid><orcidid>https://orcid.org/0000-0001-5132-9197</orcidid><orcidid>https://orcid.org/0000-0001-5310-5306</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2164-5515
ispartof Human vaccines & immunotherapeutics, 2021-09, Vol.17 (9), p.2863-2867
issn 2164-5515
2164-554X
language eng
recordid cdi_crossref_primary_10_1080_21645515_2021_1913964
source MEDLINE; PubMed (Medline); Alma/SFX Local Collection
subjects Child
China - epidemiology
clinical pharmacists
COVID-19
COVID-19 Vaccines
Humans
Pharmacists
Research Paper
safety
SARS-CoV-2
Vaccination
vaccine
title Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T18%3A18%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20survey%20by%20clinical%20pharmacists%20on%20COVID-19%20vaccination%20from%20a%20single%20center%20in%20China&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Wang,%20Guangfei&rft.date=2021-09-02&rft.volume=17&rft.issue=9&rft.spage=2863&rft.epage=2867&rft.pages=2863-2867&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2021.1913964&rft_dat=%3Cproquest_cross%3E2518226960%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2518226960&rft_id=info:pmid/33886411&rft_doaj_id=oai_doaj_org_article_76c4bd82362d49f1b7881436fe12f78b&rfr_iscdi=true